Floatz logo

Semaglutide

Mobility Disability

Veru Inc.protein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Mobility Disability cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Stanford University
Phase 4BB
Tirzepatide
Pennington Biomedical Research Center
Phase 4BB
L-Ofloxacin
Children's Oncology Group
Phase 3BB
TESTOSTERONE UNDECYLATE
Alliance for Clinical Trials in Oncology
Phase 3BB
Naproxen
Gary Morrow
Phase 3BB

View all 19 →

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
81 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →